Erythropoietin promoted the proliferation of hepatocellular carcinoma through hypoxia induced translocation of its specific receptor

被引:21
|
作者
Miao, Shuo [1 ]
Wang, Su-Mei [1 ]
Cheng, Xue [1 ]
Li, Yao-Feng [1 ]
Zhang, Qing-Song [2 ]
Li, Gang [3 ]
He, Song-Qing [4 ]
Chen, Xiao-Ping [5 ]
Wu, Ping [1 ]
机构
[1] Huazhong Univ Sci & Technol, Dept Pathophysiol, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technolgy, Tongji Hosp, Dept Surg, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China
[3] Huazhong Univ Sci & Technol, Liyuan Hosp, Dept Surg, Tongji Med Coll, Wuhan 430074, Hubei, Peoples R China
[4] Guangxi Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Nanning 530021, Peoples R China
[5] Huazhong Univ Sci & Technolgy, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan 430030, Hubei, Peoples R China
来源
CANCER CELL INTERNATIONAL | 2017年 / 17卷
基金
中国国家自然科学基金;
关键词
Erythropoietin; Erythropoietin receptor; Hepatocellular carcinoma; Hypoxia; Proliferation; PHASE-III TRIAL; DOUBLE-BLIND; SERUM ERYTHROPOIETIN; CANCER-PATIENTS; STIMULATING AGENTS; EPOETIN-ALPHA; TUMOR-GROWTH; CHEMOTHERAPY; EXPRESSION; ANEMIA;
D O I
10.1186/s12935-017-0494-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Erythropoietin (EPO) is a hypoxia-inducible stimulator of erythropoiesis. Besides its traditional application in anemia therapy, it offers an effective treatment in the cancer patients, especially those who receive chemotherapy. Several reports indicated that it could promote the tumor cell proliferation through its specific receptor (EPOR). Unfortunately, the role of EPO/EPOR in hepatocellular carcinoma (HCC) progressing is still uncertain. Methods: Protein in tumor tissue from HCC patients or H22 tumor-bearing mice was detected with immunohistochemistry. Cells were cultured under 1% oxygen to establish hypoxia. RT-PCR and western blotting were used to measure mRNA and protein of EPO/EPOR, respectively. MTT, flow cytometry and PCNA staining were used to detect cell proliferation. Immunofluorescence staining was applied to study the expression and location of cellular EPOR. The EPOR binding studies were performed with 125I-EPO radiolabeling assay. Results: EPO and EPOR protein were up-regulated in HCC tissue of patients and H22-bearing mice. These were positively correlated with hypoxia-inducible factor -1 alpha and ki-67. Hypoxia up-regulated the expression of EPO and EPOR in HepG2 cells. It also induced the proliferation and increased the percentage of divided cells after 24, 48 and 72 h treatment. These were inhibited in cells pre-treated with 0.5 mu g/mL soluble-EPOR. Immunofluorescence staining presented that EPOR was obviously translocated from nucleus to cytoplasm and membrane under hypoxia. EPOR binding activity was also increased after exposure to hypoxia. Recombinant human erythropoietin obviously elevated cell proliferation rate and the percentage of divided under hypoxia but not normoxia, which were also inhibited by soluble-EPOR. Conclusions: Our result indicated for the first time that EPO promoted the proliferation of HCC cells through hypoxia induced translocation of it specific receptor.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Erythropoietin promoted the proliferation of hepatocellular carcinoma through hypoxia induced translocation of its specific receptor
    Shuo Miao
    Su-Mei Wang
    Xue Cheng
    Yao-Feng Li
    Qing-Song Zhang
    Gang Li
    Song-Qing He
    Xiao-Ping Chen
    Ping Wu
    Cancer Cell International, 17
  • [2] Erythropoietin and erythropoietin receptor in hepatocellular carcinoma: correlation with vasculogenic mimicry and poor prognosis
    Yang, Zhihong
    Sun, Baocun
    Zhao, Xiulan
    Shao, Bing
    An, Jindan
    Gu, Qiang
    Wang, Yong
    Dong, Xueyi
    Zhang, Yanhui
    Qiu, Zhiqiang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (04): : 4033 - 4043
  • [3] Correlation of adrenomedullin with the erythropoietin receptor and microvessel density in hepatocellular carcinoma
    Qu, Zhen
    Jiang, Yong
    Xu, Ming
    Lu, Ming Zhu
    Zhou, Bin
    Ding, Yitao
    ARCHIVES OF MEDICAL SCIENCE, 2015, 11 (05) : 978 - 981
  • [4] Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma
    Ribatti, D.
    Marzullo, A.
    Gentile, A.
    Longo, V.
    Nico, B.
    Vacca, A.
    Dammacco, F.
    HISTOPATHOLOGY, 2007, 50 (05) : 591 - 596
  • [5] Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression
    Maegdefrau, Ulrike
    Amann, Thomas
    Winklmeier, Andreas
    Braig, Simone
    Schubert, Thomas
    Weiss, Thomas S.
    Schardt, Katharina
    Warnecke, Christina
    Hellerbrand, Claus
    Bosserhoff, Anja-Katrin
    JOURNAL OF PATHOLOGY, 2009, 218 (04) : 520 - 529
  • [6] Hypoxia-induced TRPM7 promotes glycolytic metabolism and progression in hepatocellular carcinoma
    Zhao, Fengbo
    Yu, Weili
    Hu, Jingyan
    Xia, Yi
    Li, Yuxuan
    Liu, Siqi
    Liu, Aifen
    Wang, Chengniu
    Zhang, Hong
    Zhang, Lei
    Shi, Jianwu
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 974
  • [7] MiR-21 promoted proliferation and migration in hepatocellular carcinoma through negative regulation of Navigator-3
    Wang, Zhipeng
    Yang, Huan
    Ren, Lei
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 464 (04) : 1228 - 1234
  • [8] Expression of erythropoietin and its receptor increases in colonic neoplastic progression: The role of hypoxia in tumorigenesis
    Gombos, Zoltan
    Danihel, Ludovit
    Repiska, Vanda
    Acs, Geza
    Furth, Emma
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2011, 54 (02) : 273 - 278
  • [9] Hypoxia-induced angiogenesis in human hepatocellular carcinoma
    Kim, KR
    Moon, HE
    Kim, KW
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2002, 80 (11): : 703 - 714
  • [10] Metformin suppresses hypoxia-induced stabilization of HIF-1′ through reprogramming of oxygen metabolism in hepatocellular carcinoma
    Zhou, Xinke
    Chen, Jitao
    Yi, Gao
    Deng, Min
    Liu, Hao
    Liang, Min
    Shi, Boyun
    Fu, Xin
    Chen, Yuqin
    Chen, Liangcai
    He, Zhimin
    Wang, Jian
    Liu, Jifang
    ONCOTARGET, 2016, 7 (01) : 873 - 884